TCRX - TScan Therapeutics, Inc.
IEX Last Trade
3
-0.050 -1.667%
Share volume: 30
Last Updated: Fri 27 Dec 2024 03:30:19 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-1.15%
PREVIOUS CLOSE
CHG
CHG%
$3.05
-0.05
-1.64%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-10 | 2022-11-09 | 2023-03-08 | 2023-05-10 | 2023-08-10 | 2023-11-09 | 2024-03-06 | 2024-05-13 | |
| Total revenue | 4.056 M | 3.363 M | 3.095 M | 6.803 M | 3.148 M | 3.887 M | 7.211 M | 566.000 K | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 4.056 M | 3.363 M | 3.095 M | 6.803 M | 3.148 M | 3.887 M | 7.211 M | 566.000 K | |
| -17.09% | -7.97% | 119.81% | -53.73% | 23.48% | 85.52% | -92.15% | |||
| Operating expenses | 19.302 M | 19.941 M | 21.744 M | 29.546 M | 27.758 M | 28.635 M | 28.568 M | 31.939 M | |
| Selling general and admin | 4.808 M | 4.910 M | 6.140 M | 7.767 M | 6.531 M | 5.894 M | 6.162 M | 7.082 M | |
| Research and development | 14.494 M | 15.031 M | 15.604 M | 21.779 M | 21.227 M | 22.741 M | 22.406 M | 24.857 M | |
| Total expenses | 19.302 M | 19.941 M | 21.744 M | 29.546 M | 27.758 M | 28.635 M | 28.568 M | 31.939 M | |
| 3.31% | 9.04% | 35.88% | -6.05% | 3.16% | -0.23% | 11.80% | |||
| Operating income | -15.246 M | -16.578 M | -18.649 M | -22.743 M | -24.610 M | -24.748 M | -21.357 M | -31.373 M | |
| Ebit | -15.246 M | -16.578 M | -18.649 M | -22.743 M | -24.610 M | -24.748 M | -21.357 M | -31.373 M | |
| Pretax income | -15.097 M | -16.245 M | -18.723 M | -22.563 M | -24.045 M | -22.997 M | -19.613 M | -30.142 M | |
| 7.60% | 15.25% | 20.51% | 6.57% | -4.36% | -14.71% | 53.68% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -15.097 M | -16.245 M | -18.723 M | -22.563 M | -24.045 M | -22.997 M | -19.613 M | -30.142 M | |
| -7.60% | -15.25% | -20.51% | -6.57% | 4.36% | 14.71% | -53.68% | |||
| Net income | -15.097 M | -16.245 M | -18.723 M | -22.563 M | -24.045 M | -22.997 M | -19.613 M | -30.142 M | |
| -7.60% | -15.25% | -20.51% | -6.57% | 4.36% | 14.71% | -53.68% |